Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385411 | 0.83 | DAO (0.49) | DAOHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL7837587 | 0.80 | DAO (0.46) | DAONOX4HPGDMEN1KMT2A | |
| SCHEMBL6483068 | 0.73 | DAO (0.54) | DAONOX4HPGDMEN1KMT2A | |
| SCHEMBL9646889 | 0.73 | NOX4 (0.49) | DAONOX4HPGDMEN1KMT2A | |
| SCHEMBL7251013 | 0.72 | L3MBTL1 (0.67) | DAOHSD17B10NOX4HPGDMEN1 | |
| SCHEMBL21055329 | 0.72 | MEN1 (0.51) | DAOHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL2621662 | 0.71 | POLB (0.47) | DAONOX4MEN1KMT2ALMNA | |
| SCHEMBL17696412 | 0.69 | MAPT (0.46) | DAOHSD17B10HPGDMEN1KMT2A | |
| SCHEMBL9645952 | 0.69 | ALOX5 (0.70) | HPGDALDH1A1KDM4E | |
| SCHEMBL11445813 | 0.68 | KDM4E (0.39) | HSD17B10HPGDMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919323-B2 | Pyridazinone inhibitors of fatty acid binding protein and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030040516-A1 | Pyrazinone inhibitors of fatty acid binding protein and method | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040516-A1 | Pyrazinone inhibitors of fatty acid binding protein and method | FABP1, FABP4, AP2B1 | DAO 3509/4885HSD17B10 298/4885NOX4 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.